Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Cerebrospinal fluid cytokine dynamics differ between Alzheimer disease patients and elderly controls.

Llano DA, Li J, Waring JF, Ellis T, Devanarayan V, Witte DG, Lenz RA.

Alzheimer Dis Assoc Disord. 2012 Oct-Dec;26(4):322-8. doi: 10.1097/WAD.0b013e31823b2728.

PMID:
22089638
2.

Comparing levels of biochemical markers in CSF from cannulated and non-cannulated rats.

Cassar SC, Tovcimak AE, Rustay NR, Ellis TA, Hooker BA, Witte DG, Li J, Buck WR, Scharf D, Muller U, Jeromin A, Wang KK, Waring JF.

J Neurosci Methods. 2010 Oct 15;192(2):249-53. doi: 10.1016/j.jneumeth.2010.07.042. Epub 2010 Aug 6.

PMID:
20692294
3.

Rigidified 2-aminopyrimidines as histamine H4 receptor antagonists: effects of substitution about the rigidifying ring.

Koenig JR, Liu H, Drizin I, Witte DG, Carr TL, Manelli AM, Milicic I, Strakhova MI, Miller TR, Esbenshade TA, Brioni JD, Cowart M.

Bioorg Med Chem Lett. 2010 Mar 15;20(6):1900-4. doi: 10.1016/j.bmcl.2010.01.131. Epub 2010 Feb 1.

PMID:
20171098
4.

H4 receptor antagonism exhibits anti-nociceptive effects in inflammatory and neuropathic pain models in rats.

Hsieh GC, Chandran P, Salyers AK, Pai M, Zhu CZ, Wensink EJ, Witte DG, Miller TR, Mikusa JP, Baker SJ, Wetter JM, Marsh KC, Hancock AA, Cowart MD, Esbenshade TA, Brioni JD, Honore P.

Pharmacol Biochem Behav. 2010 Mar;95(1):41-50. doi: 10.1016/j.pbb.2009.12.004. Epub 2009 Dec 11.

PMID:
20004681
5.

Design of a new histamine H3 receptor antagonist chemotype: (3aR,6aR)-5-alkyl-1-aryl-octahydropyrrolo[3,4-b]pyrroles, synthesis, and structure-activity relationships.

Zhao C, Sun M, Bennani YL, Miller TR, Witte DG, Esbenshade TA, Wetter J, Marsh KC, Hancock AA, Brioni JD, Cowart MD.

J Med Chem. 2009 Aug 13;52(15):4640-9. doi: 10.1021/jm900480x.

PMID:
19588934
6.

In vitro and in vivo characterization of A-940894: a potent histamine H4 receptor antagonist with anti-inflammatory properties.

Strakhova MI, Cuff CA, Manelli AM, Carr TL, Witte DG, Baranowski JL, Vortherms TA, Miller TR, Rundell L, McPherson MJ, Adair RM, Brito AA, Bettencourt BM, Yao BB, Wetter JM, Marsh KC, Liu H, Cowart MD, Brioni JD, Esbenshade TA.

Br J Pharmacol. 2009 May;157(1):44-54. doi: 10.1111/j.1476-5381.2009.00236.x.

7.

cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.

Liu H, Altenbach RJ, Carr TL, Chandran P, Hsieh GC, Lewis LG, Manelli AM, Milicic I, Marsh KC, Miller TR, Strakhova MI, Vortherms TA, Wakefield BD, Wetter JM, Witte DG, Honore P, Esbenshade TA, Brioni JD, Cowart MD.

J Med Chem. 2008 Nov 27;51(22):7094-8. doi: 10.1021/jm8007618.

PMID:
18983139
8.

Cloning and characterization of the monkey histamine H3 receptor isoforms.

Strakhova MI, Fox GB, Carr TL, Witte DG, Vortherms TA, Manelli AM, Miller TR, Yao BB, Brioni JD, Esbenshade TA.

Eur J Pharmacol. 2008 Dec 28;601(1-3):8-15. doi: 10.1016/j.ejphar.2008.10.026. Epub 2008 Oct 21.

PMID:
18977214
9.

Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.

Cowart MD, Altenbach RJ, Liu H, Hsieh GC, Drizin I, Milicic I, Miller TR, Witte DG, Wishart N, Fix-Stenzel SR, McPherson MJ, Adair RM, Wetter JM, Bettencourt BM, Marsh KC, Sullivan JP, Honore P, Esbenshade TA, Brioni JD.

J Med Chem. 2008 Oct 23;51(20):6547-57. doi: 10.1021/jm800670r. Epub 2008 Sep 26.

PMID:
18817367
10.

Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.

Altenbach RJ, Adair RM, Bettencourt BM, Black LA, Fix-Stenzel SR, Gopalakrishnan SM, Hsieh GC, Liu H, Marsh KC, McPherson MJ, Milicic I, Miller TR, Vortherms TA, Warrior U, Wetter JM, Wishart N, Witte DG, Honore P, Esbenshade TA, Hancock AA, Brioni JD, Cowart MD.

J Med Chem. 2008 Oct 23;51(20):6571-80. doi: 10.1021/jm8005959. Epub 2008 Sep 24.

PMID:
18811133
11.

The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.

Zhao C, Sun M, Bennani YL, Gopalakrishnan SM, Witte DG, Miller TR, Krueger KM, Browman KE, Thiffault C, Wetter J, Marsh KC, Hancock AA, Esbenshade TA, Cowart MD.

J Med Chem. 2008 Sep 11;51(17):5423-30. doi: 10.1021/jm8003625. Epub 2008 Aug 7.

PMID:
18683917
12.

A robust and high-capacity [(35)S]GTPgammaS binding assay for determining antagonist and inverse agonist pharmacological parameters of histamine H(3) receptor ligands.

Miller TR, Baranowski JL, Estvander BR, Witte DG, Carr TL, Manelli AM, Krueger KM, Cowart MD, Brioni JD, Esbenshade TA.

Assay Drug Dev Technol. 2008 Jun;6(3):339-49. doi: 10.1089/adt.2007.118.

PMID:
18593375
13.

An 80-amino acid deletion in the third intracellular loop of a naturally occurring human histamine H3 isoform confers pharmacological differences and constitutive activity.

Bongers G, Krueger KM, Miller TR, Baranowski JL, Estvander BR, Witte DG, Strakhova MI, van Meer P, Bakker RA, Cowart MD, Hancock AA, Esbenshade TA, Leurs R.

J Pharmacol Exp Ther. 2007 Dec;323(3):888-98. Epub 2007 Sep 12.

PMID:
17855474
14.

A new family of histamine H3 receptor antagonists based on a natural product: discovery, SAR, and properties of the series.

Cowart M, Sun M, Zhao C, Witte DG, Miller TR, Krueger KM, Browman K, Fox GB, Bennani YL, Esbenshade TA, Hancock AA.

Inflamm Res. 2007 Apr;56 Suppl 1:S47-8. No abstract available.

PMID:
17806176
15.

Novel heterocyclic-substituted benzofuran histamine H3 receptor antagonists: in vitro properties, drug-likeness, and behavioral activity.

Cowart M, Gfesser GA, Browman KE, Faghih R, Miller TR, Milicic I, Baranowski JL, Krueger KM, Witte DG, Molesky AL, Komater VA, Buckley MJ, Diaz GJ, Gagne GD, Zhou D, Deng X, Pan L, Roberts EM, Diehl MS, Wetter JM, Marsh KC, Fox GB, Brioni JD, Esbenshade TA, Hancock AA.

Biochem Pharmacol. 2007 Apr 15;73(8):1243-55. Epub 2007 Feb 23.

PMID:
17371699
16.

Detection of multiple H3 receptor affinity states utilizing [3H]A-349821, a novel, selective, non-imidazole histamine H3 receptor inverse agonist radioligand.

Witte DG, Yao BB, Miller TR, Carr TL, Cassar S, Sharma R, Faghih R, Surber BW, Esbenshade TA, Hancock AA, Krueger KM.

Br J Pharmacol. 2006 Jul;148(5):657-70. Epub 2006 May 22.

17.

Differences in pharmacological properties of histamine H(3) receptor agonists and antagonists revealed at two human H (3) receptor isoforms.

Esbenshade TA, Krueger KM, Yao BB, Witte DG, Estvander BR, Baranowski JL, Miller TR, Hancock AA.

Inflamm Res. 2006 Apr;55 Suppl 1:S45-6. No abstract available.

PMID:
16705378
18.

Differential CNS expression and functional activity of multiple human H(3) receptor isoforms.

Esbenshade TA, Strakhova MI, Carr TL, Sharma R, Witte DG, Yao BB, Miller TR, Hancock AA.

Inflamm Res. 2006 Apr;55 Suppl 1:S38-9. No abstract available.

PMID:
16547816
19.

Use of an inverse agonist radioligand [3H]A-317920 reveals distinct pharmacological profiles of the rat histamine H3 receptor.

Yao BB, Witte DG, Miller TR, Carr TL, Kang CH, Cassar S, Faghih R, Bennani YL, Surber BW, Hancock AA, Esbenshade TA.

Neuropharmacology. 2006 Mar;50(4):468-78. Epub 2005 Nov 28.

PMID:
16316670
20.

Use of novel, non-imidazole inverse agonist radioligands to define histamine H3 receptor pharmacology.

Esbenshade TA, Yao BB, Witte DG, Carr TL, Sharma R, Baranowski JL, Krueger KM, Miller TR, Surber BW, Faghih R, Hancock AA.

Inflamm Res. 2005 Apr;54 Suppl 1:S46-7. No abstract available.

PMID:
15928830
21.

G protein-dependent pharmacology of histamine H3 receptor ligands: evidence for heterogeneous active state receptor conformations.

Krueger KM, Witte DG, Ireland-Denny L, Miller TR, Baranowski JL, Buckner S, Milicic I, Esbenshade TA, Hancock AA.

J Pharmacol Exp Ther. 2005 Jul;314(1):271-81. Epub 2005 Apr 8.

PMID:
15821027
22.

Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties.

Esbenshade TA, Fox GB, Krueger KM, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Pan L, Wetter J, Marsh K, Bennani YL, Cowart MD, Sullivan JP, Hancock AA.

J Pharmacol Exp Ther. 2005 Apr;313(1):165-75. Epub 2004 Dec 17.

PMID:
15608078
23.

Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist.

Esbenshade TA, Fox GB, Krueger KM, Baranowski JL, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Pan JB, Faghih R, Bennani YL, Williams M, Hancock AA.

Biochem Pharmacol. 2004 Sep 1;68(5):933-45.

PMID:
15294456
24.

Structure-activity relationships of A-331440: a new histamine-3 antagonist with anti-obesity properties.

Faghih R, Esbenshade TA, Krueger KM, Yao BB, Witte DG, Miller TM, Kang CH, Fox GB, Cowart M, Bennani YL, Hancock AA.

Inflamm Res. 2004 Mar;53 Suppl 1:S79-80. Epub 2004 Mar 5. No abstract available.

PMID:
15054629
25.

Antiobesity effects of A-331440, a novel non-imidazole histamine H3 receptor antagonist.

Hancock AA, Bennani YL, Bush EN, Esbenshade TA, Faghih R, Fox GB, Jacobson P, Knourek-Segel V, Krueger KM, Nuss ME, Pan JB, Shapiro R, Witte DG, Yao BB.

Eur J Pharmacol. 2004 Mar 8;487(1-3):183-97.

PMID:
15033391
26.

Use of a fluorescent imaging plate reader--based calcium assay to assess pharmacological differences between the human and rat vanilloid receptor.

Witte DG, Cassar SC, Masters JN, Esbenshade T, Hancock AA.

J Biomol Screen. 2002 Oct;7(5):466-75.

PMID:
14599363
27.

In vitro pharmacological properties of two novel non-imidazole H3 receptor (H3R) antagonists.

Yao BB, Witte DG, Miller TR, Krueger KM, Carr TL, Kang CH, Faghih R, Bennani YL, Esbenshade TA, Hancock AA.

Inflamm Res. 2003 Apr;52 Suppl 1:S45-6. No abstract available.

PMID:
12755405
28.

Differential activation of dual signaling responses by human H1 and H2 histamine receptors.

Esbenshade TA, Kang CH, Krueger KM, Miller TR, Witte DG, Roch JM, Masters JN, Hancock AA.

J Recept Signal Transduct Res. 2003 Feb;23(1):17-31.

PMID:
12680587
29.

Two novel and selective nonimidazole histamine H3 receptor antagonists A-304121 and A-317920: I. In vitro pharmacological effects.

Esbenshade TA, Krueger KM, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Fox GB, Faghih R, Bennani YL, Williams M, Hancock AA.

J Pharmacol Exp Ther. 2003 Jun;305(3):887-96. Epub 2003 Feb 20.

PMID:
12606603
30.

Modeling of relationships between pharmacokinetics and blockade of agonist-induced elevation of intraurethral pressure and mean arterial pressure in conscious dogs treated with alpha(1)-adrenoceptor antagonists.

Witte DG, Brune ME, Katwala SP, Milicic I, Stolarik D, Hui YH, Marsh KC, Kerwin JF Jr, Meyer MD, Hancock AA.

J Pharmacol Exp Ther. 2002 Feb;300(2):495-504.

PMID:
11805209
31.

Effect of fiduxosin, an antagonist selective for alpha(1A)- and alpha(1D)-adrenoceptors, on intraurethral and arterial pressure responses in conscious dogs.

Brune ME, Katwala SP, Milicic I, Witte DG, Kerwin JF Jr, Meyer MD, Hancock AA, Williams M.

J Pharmacol Exp Ther. 2002 Feb;300(2):487-94.

PMID:
11805208
32.

Analysis of Apparent Noncompetitive Responses to Competitive H(1)-Histamine Receptor Antagonists in Fluorescent Imaging Plate Reader-Based Calcium Assays.

Miller TR, Witte DG, Ireland LM, Kang CH, Roch JM, Masters JN, Esbenshade TA, Hancock AA.

J Biomol Screen. 1999;4(5):249-258.

PMID:
10838445
33.

Actions of A-131701, a novel, selective antagonist for alpha-1A compared with alpha-1B adrenoceptors on intraurethral and blood pressure responses in conscious dogs and a pharmacodynamic assessment of in vivo prostatic selectivity.

Hancock AA, Brune ME, Witte DG, Marsh KC, Katwala S, Milicic I, Ireland LM, Crowell D, Meyer MD, Kerwin JF Jr.

J Pharmacol Exp Ther. 1998 May;285(2):628-42.

PMID:
9580607
35.

Characterization of cloned human dopamine D1 receptor-mediated calcium release in 293 cells.

Lin CW, Miller TR, Witte DG, Bianchi BR, Stashko M, Manelli AM, Frail DE.

Mol Pharmacol. 1995 Jan;47(1):131-9.

PMID:
7838121
36.

Regulation of the release of interleukin-6 from human astrocytoma cells.

Cadman ED, Witte DG, Lee CM.

J Neurochem. 1994 Sep;63(3):980-7.

PMID:
7519668
37.

CCK-A-selective tetrapeptides containing lys(N epsilon)-amide residues: favorable in vivo and in vitro effects of N-methylation at the aspartyl residue.

Bennett MJ, Nikkel AL, Bianchi BR, Miller TR, Bednarz L, Witte DG, Stashko M, Wang SS, Gore PA, Asin KE, et al.

J Med Chem. 1994 May 27;37(11):1569-71.

PMID:
8201591
38.

Novel Asp32-replacement tetrapeptide analogues as potent and selective CCK-A agonists.

Elliott RL, Kopecka H, Tufano MD, Shue YK, Gauri AJ, Lin CW, Bianchi BR, Miller TR, Witte DG, Stashko MA, et al.

J Med Chem. 1994 May 27;37(11):1562-8.

PMID:
8201590
39.

Tetrapeptide CCK-A agonists: effect of backbone N-methylations on in vitro and in vivo CCK activity.

Holladay MW, Kopecka H, Miller TR, Bednarz L, Nikkel AL, Bianchi BR, Witte DG, Shiosaki K, Lin CW, Asin KE, et al.

J Med Chem. 1994 Mar 4;37(5):630-5.

PMID:
8126703
40.
41.

Tetrapeptide CCK agonists: structure-activity studies on modifications at the N-terminus.

Elliott RL, Kopecka H, Bennett MJ, Shue YK, Craig R, Lin CW, Bianchi BR, Miller TR, Witte DG, Stashko MA, et al.

J Med Chem. 1994 Jan 21;37(2):309-13.

PMID:
8295219
42.

Cloning and characterization of a truncated dopamine D1 receptor from goldfish retina: stimulation of cyclic AMP production and calcium mobilization.

Frail DE, Manelli AM, Witte DG, Lin CW, Steffey ME, Mackenzie RG.

Mol Pharmacol. 1993 Dec;44(6):1113-8.

PMID:
8264547
43.

Double bond isosteres of the peptide bond: synthesis and biological activity of cholecystokinin (CCK) C-terminal hexapeptide analogs.

Shue YK, Tufano MD, Carrera GM Jr, Kopecka H, Kuyper SL, Holladay MW, Lin CW, Witte DG, Miller TR, Stashko M, et al.

Bioorg Med Chem. 1993 Sep;1(3):161-71.

PMID:
8081848
44.

Identification and characterization of type A endothelin receptors in MMQ cells.

Wu-Wong JR, Chiou W, Magnuson SR, Witte DG, Lin CW.

Mol Pharmacol. 1993 Aug;44(2):285-91.

PMID:
8355666
45.

Peripheral cholecystokinin type A receptors mediate oxytocin secretion in vivo.

Miller TR, Bianchi BR, Witte DG, Lin CW.

Regul Pept. 1993 Jan 22;43(1-2):107-12.

PMID:
8426907
46.

Characterization of the novel CCK analogs JMV-180, JMV-320, and JMV-332 in H345 cells.

Witte DG, Nadzan AM, Martinez J, Rodriguez M, Lin CW.

Peptides. 1992 Nov-Dec;13(6):1227-32.

PMID:
1337381
47.

Synthesis and biological activity of CCK heptapeptide analogues. Effects of conformational constraints and standard modifications on receptor subtype selectivity, functional activity in vitro, and appetite suppression in vivo.

Holladay MW, Bennett MJ, Tufano MD, Lin CW, Asin KE, Witte DG, Miller TR, Bianchi BR, Nikkel AL, Bednarz L, et al.

J Med Chem. 1992 Aug 7;35(16):2919-28.

PMID:
1501220
48.

Both CCK-A and CCK-B/gastrin receptors mediate pepsinogen release in guinea pig gastric glands.

Lin CW, Bianchi BR, Miller TR, Witte DG, Wolfram CA.

Am J Physiol. 1992 Jun;262(6 Pt 1):G1113-20.

PMID:
1616041
49.

Development of potent and selective CCK-A receptor agonists from Boc-CCK-4: tetrapeptides containing Lys(N epsilon)-amide residues.

Shiosaki K, Lin CW, Kopecka H, Craig RA, Bianchi BR, Miller TR, Witte DG, Stashko M, Nadzan AM.

J Med Chem. 1992 May 29;35(11):2007-14.

PMID:
1375964
50.

Boc-CCK-4 derivatives containing side-chain ureas as potent and selective CCK-a receptor agonists.

Shiosaki K, Lin CW, Kopecka H, Tufano MD, Bianchi BR, Miller TR, Witte DG, Nadzan AM.

J Med Chem. 1991 Sep;34(9):2837-42.

PMID:
1716682

Supplemental Content

Loading ...
Support Center